Profile data is unavailable for this security.
About the company
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Company’s customers are pharmaceutical companies worldwide.
- Revenue in NOK (TTM)423.59m
- Net income in NOK61.37m
- Incorporated2015
- Employees77.00
- LocationVistin Pharma ASAOstensjoveien 27OSLO 0661NorwayNOR
- Phone+47 35984200
- Websitehttps://www.vistin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipum AB (publ) | 0.00 | -40.17m | 314.85m | 5.00 | -- | 6.44 | -- | -- | -3.17 | -3.17 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -92.41 | -127.85 | -120.33 | -184.50 | -- | -- | -- | -293,228.70 | -- | -328.75 | 0.1979 | -- | -- | -- | 2.38 | -- | -- | -- |
| Dicot Pharma AB | 238.60k | -52.15m | 382.37m | 3.00 | -- | 13.38 | -- | 1,602.57 | -0.0505 | -0.0505 | 0.0002 | 0.0157 | 0.0054 | 9.26 | 0.079 | 77,696.66 | -117.97 | -- | -144.43 | -- | -19,313.23 | -- | -21,855.92 | -- | 1.98 | -- | 0.00 | -- | 89.43 | -- | -39.05 | -- | -- | -- |
| Orexo AB | 609.88m | -107.79m | 387.28m | 113.00 | -- | -- | -- | 0.635 | -3.05 | -3.05 | 17.28 | -0.7896 | 0.7609 | 1.17 | 2.32 | 5,136,207.00 | -13.45 | -6.41 | -20.81 | -9.99 | 88.28 | 86.76 | -17.67 | -11.83 | 1.47 | -0.7557 | 1.05 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Navamedic ASA | 543.49m | 24.64m | 406.24m | 45.00 | 16.49 | 1.64 | 10.19 | 0.7475 | 1.39 | 1.39 | 31.30 | 14.00 | 1.08 | 3.60 | 4.21 | 12,077,510.00 | 4.91 | 0.039 | 7.35 | 0.0635 | 40.04 | 38.33 | 4.53 | 0.038 | 0.8753 | 3.63 | 0.3686 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
| Enzymatica AB (publ) | 46.01m | -57.27m | 447.25m | 16.00 | -- | 4.80 | -- | 9.72 | -0.309 | -0.309 | 0.2485 | 0.3747 | 0.3461 | 1.19 | 8.20 | 2,497,333.00 | -43.08 | -27.36 | -45.77 | -33.98 | 63.99 | 65.08 | -124.47 | -66.12 | -- | -24.43 | 0.2789 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -145.63m | 515.70m | 9.00 | -- | 2.20 | -- | -- | -10.57 | -10.57 | 0.00 | 17.57 | 0.00 | -- | -- | 0.00 | -46.35 | -16.11 | -54.97 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -35.52m | 578.66m | 3.00 | -- | 5.55 | -- | -- | -0.2164 | -0.2164 | 0.00 | 0.6309 | 0.00 | -- | -- | 0.00 | -24.29 | -66.73 | -28.91 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| Moberg Pharma AB (publ) | 5.05m | -23.29m | 629.79m | 9.00 | -- | 0.6339 | -- | 124.82 | -0.9608 | -0.9608 | 0.1936 | 20.27 | 0.0065 | -- | 0.4949 | -- | -3.02 | -- | -3.12 | -- | 65.19 | -- | -461.64 | -- | 12.32 | -- | 0.0043 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| Magle Chemoswed Holding AB | 211.06m | 17.14m | 685.66m | 78.00 | 23.48 | 0.8069 | 16.85 | 3.25 | 1.55 | 1.55 | 19.09 | 45.11 | 0.365 | 0.3327 | 8.15 | 2,643,474.00 | 2.96 | 2.52 | 3.92 | 3.52 | 88.98 | 85.67 | 8.12 | 3.92 | 0.4894 | 4.19 | 0.2994 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| IRLAB Therapeutics AB | 51.81m | -115.38m | 739.52m | 32.00 | -- | 19.03 | -- | 14.27 | -2.17 | -2.17 | 0.9759 | 0.7332 | 0.2916 | -- | 3.58 | 1,946,769.00 | -64.93 | -27.12 | -118.29 | -30.42 | -138.17 | -72.18 | -222.69 | -155.57 | -- | -21.72 | 0.6132 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Vistin Pharma ASA | 423.59m | 61.37m | 1.18bn | 77.00 | 19.22 | 3.80 | 14.69 | 2.78 | 1.38 | 1.38 | 9.55 | 7.01 | 1.09 | 1.89 | 7.27 | 5,501,130.00 | 15.85 | 1.73 | 19.26 | 2.11 | 64.84 | 58.92 | 14.49 | 2.36 | 1.06 | 21.05 | 0.0178 | 222.57 | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
| Photocure ASA | 513.58m | 12.84m | 1.44bn | 102.00 | 114.30 | 2.89 | 34.53 | 2.81 | 0.4655 | 0.4655 | 18.98 | 18.43 | 0.7233 | 0.8802 | 7.86 | 5,035,059.00 | 1.81 | -3.06 | 2.01 | -3.54 | 94.52 | 93.64 | 2.50 | -5.15 | 5.30 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
| Probi AB | 645.28m | 11.14m | 3.15bn | 157.00 | 282.65 | 2.25 | 27.45 | 4.88 | 0.9552 | 0.9552 | 55.33 | 120.07 | 0.4049 | 3.24 | 7.14 | 3,939,931.00 | 0.6991 | 4.64 | 0.7409 | 4.98 | 33.18 | 42.04 | 1.73 | 9.83 | 4.83 | -- | 0.0561 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
Data as of Nov 05 2024. Currency figures normalised to Vistin Pharma ASA's reporting currency: Norwegian Krone NOK
12.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Holmen Fondsforvaltning ASas of 31 Dec 2023 | 3.84m | 8.66% |
| MP Pensjon PKas of 31 Dec 2023 | 1.72m | 3.88% |
Data from 25 Jun 2024 - 10 Sep 2024Source: FactSet Research Systems Inc.
